Swallow, Elizabeth A.Aref, Mohammad W.Chen, NealByiringo, InnocentHammond, Max A.McCarthy, Brian P.Territo, Paul R.Kamocka, Malgorzata M.Winfree, SethDunn, Kenneth W.Moe, Sharon M.Allen, Matthew R.2019-08-022019-08-022018-09-01Swallow EA, Aref MW, Chen N, Byiringiro I, Hammond MA, McCarthy BP, Territo PR, Kamocka MM, Winfree S, Dunn KW, Moe SM. Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease. Osteoporosis International. 2018 Sep 1;29(9):2139-46.https://hdl.handle.net/1805/20148This work examines the skeletal accumulation of fluorescently-tagged zoledronate in an animal model of chronic kidney disease. The results show higher accumulation 24-hours post-dose in animals with lower kidney function due to greater amounts of binding at individual surfaces.Bone Density Conservation AgentsBone and BonesChronic Renal InsufficiencyZoledronic AcidArticle